Journal article
A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes
M Chao, S Spencer, M Guerrieri, W Ding, M Goharian, H Ho, M Ng, D Healey, A Tan, C Cham, DL Joon, N Lawrentschuk, D Travis, S Sengupta, Y Chan, A Troy, T Pham, D Clarke, P Liodakis, D Bolton
Journal of Contemporary Brachytherapy | TERMEDIA PUBLISHING HOUSE LTD | Published : 2018
Abstract
Purpose: To report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer. Material and methods: Between 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation. Follow-up was performed every 3 months for 12 months, then every 6 months over 4 years and included prostate specific antigen evaluation. The biochemical relapse-free survival (BRFS) was defined according to the Phoenix criteria. Acu..
View full abstract